A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over radiotherapy alone.1 Mechanisms proposed to explain this effect include ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

Moderately hypofractionated radiotherapy, both isodose and dose-escalated, led to progression-free survival outcomes similar to that achieved with conventionally fractionated radiotherapy in patients ...

Ultrahypofractionated radiotherapy yields non-inferior 10-year survival outcomes compared to conventional treatment in ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...

The 2 groups--those receiving ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy--had similar overall survival, which was 81% and 79%, respectively, at 10 years.

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...